SPOTLIGHT: Sorafenib application completed

Bayer and Onyx Pharmaceuticals have supplied the last piece of information to the FDA to support their marketing application for Sorafenib to treat advanced kidney disease. They hope to begin marketing the drug in the first half of 2006. Report

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.